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Abstract The first edition of the Italian diagnostic and
therapeutic guidelines for primary headaches in adults was
published in J Headache Pain 2(Suppl. 1):105–190 (2001).
Ten years later, the guideline committee of the Italian
Society for the Study of Headaches (SISC) decided it was
time to update therapeutic guidelines. A literature search
was carried out on Medline database, and all articles on
primary headache treatments in English, German, French
and Italian published from February 2001 to December 2011
were taken into account. Only randomized controlled trials
(RCT) and meta-analyses were analysed for each drug. If
RCT were lacking, open studies and case series were also
examined. According to the previous edition, four levels of
recommendation were defined on the basis of levels of
evidence, scientific strength of evidence and clinical effec-
tiveness. Recommendations for symptomatic and prophy-
lactic treatment of migraine and cluster headache were
therefore revised with respect to previous 2001 guidelines
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and a section was dedicated to non-pharmacological treat-
ment. This article reports a summary of the revised version
published in extenso in an Italian version.
Keywords Guidelines  Primary headaches 
Symptomatic and prophylactic treatment  Pharmacological
and non pharmacological
Introduction and methodology
Ten years after the first edition (2001), the Italian Society
for the Study of Headaches (SISC) decided to update the
diagnostic and therapeutic guidelines for primary head-
aches in adults, not only including migraine, but also ten-
sion-type headache, trigeminal-autonomic cephalgias
(TACs) and other primary headaches.
This concise version synthetically reports only treatment
aspects (including non-pharmacological treatments and
interventions), referring to the International Headache
Society classification (ICHD-II, 2004) and its Appendix for
diagnostic criteria. Therapeutic approach to other primary
headaches has already been published by the members of
Other Primary Headaches Subcommittee and therefore is
not included in this updated version of Italian Primary
Headaches Guidelines [2–5].
A literature search was performed on Medline database,
considering all the articles on primary headache diagnosis
and treatment published in English, German, French and
Italian from February 2001 to December 2011. Only ran-
domized controlled trials (RCT) and meta-analyses were
analysed for each drug, if available. Lacking RCT, open
studies and case series were also examined.
Four levels of recommendation were defined on the
basis of the levels of evidence, the scientific strength of
evidence and clinical effectiveness (Tables 1, 2, 3, 4).
Following the tradition, the management of primary
headaches is divided into acute/symptomatic (to relieve
headache attack) and preventive (to reduce frequency and
intensity of headache attacks) treatment.
Migraine
Symptomatic treatment of migraine attacks alone is recom-
mended when attacks are non-disabling or, if disabling, they
occur\4 days per month. Vice versa, a preventive treatment is
recommended when disabling migraine attacks are C4 per
Table 1 Levels of evidence
Level A: Two or more clinically controlled, randomize, double-
blind studies carried out according to good clinical practice
(GCP) versus placebo or versus an active drug for which there is
proven evidence of efficacy
Level B: One clinically controlled study according to GCP or
more than one controlled case–control study/ies or Cohort study/
ies
Level C: Favourable judgement of two-thirds of the Ad Hoc
Committee, historical controls, non-randomized studies, case
reports
Table 2 Scientific strength of evidence
??? The difference in the parameters of efficacy registered in
studies compared with placebo or another active drug has a
high level of significance (p \ 0.01; p \ 0.001;
p \ 0.0001). Adverse events are rare or occasional and not
severe
?? The difference in the parameters of efficacy registered in
studies reaches the minimum level of significance
(p \ 0.05) or the minimum clinically significant level
(difference in the parameters \15 %)a
? The difference in the efficacy parameters between the study
drug and placebo or another active drug is not statistically
significant
0 The drug is not efficacious or is characterized by severe
adverse events
a Even drugs for which the difference in the efficacy parameters
compared with placebo or another active drug is higher than the
minimum level of statistical significance, but have frequent, yet no
severe adverse events are included in this group
Table 3 Assessment of the clinical effectiveness of treatments
Symptomatic drugs
??? The majority (C60 %) of the patients had partial or total
relief of headache. More than 30 % of them were pain
free
?? Many patients (from C40 to\60 %) had partial or total relief
of headache, or 20–29 % of the patients were pain free
? Some of the patients (from 20 to\40 %) had partial or total
relief of headache. Up to 20 % were pain free
0 Less than 20 % of the treated patients received a clinical
benefit
? The members of the Ad Hoc Committee were unable to
express any judgement on effectiveness based on their
personal clinical impressions
Preventive drugs
??? The majority (C50 %) of the patients experienced a
reduction, of at least 50 %, in the frequency (and
intensity) of attacks
?? Many patients (from C30 to \50 %) experienced a
reduction, of at least 50 %, in the frequency (and
intensity) of attacks
? Some of the patients (from C20 to \30 %) experienced a
reduction, of at least 50 %, in the frequency (and
intensity) of attacks
0 Less than 20 % of the treated patients received a clinical
benefit
? The members of the Ad Hoc Committee were unable to
express any judgement on effectiveness based on their
personal clinical impressions
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month or, if \4 per month, in the case of poor response to
symptomatic treatment. As in other primary headaches, a
headache diary is a fundamental tool for monitoring attack
frequency, duration and severity [6]. It is required when deciding
the best treatment to suggest and for monitoring the effective-
ness of symptomatic and prophylactic prescribed treatment.
Acute attack treatment
1. A stratified approach, consisting in a different choice
of initial treatment based on the severity of the attack
(migraine-specific drugs, i.e. triptans, for moderate/
severe attacks and non-specific drugs like analgesics
and non-steroidal anti-inflammatory drugs (NSAIDs)
for mild/moderate attacks) is recommended [7].
2. The most appropriate drug should be taken at the
lowest useful dosage as early as possible after the
attack begins.
3. As a rule, preparations with only one active principle
should be preferred.
4. It is convenient to provide some alternatives for attacks
of different severity.
5. Rescue drugs should be provided in case of first-choice
medication failure.
Symptomatic drugs
Drugs for migraine attacks include triptans, analgesics
(NSAIDs), ergot derivatives and antiemetics.
Triptans
Indications They are indicated for the treatment of mod-
erate or severe attacks (level of recommendation I). Effi-
cacy RCT have demonstrated the efficacy of triptans, not
only for headache but also for accompanying symptoms
and functional disability [8–19] (Table 2). The consistency
of efficacy of triptans in the treatment of multiple attacks
and in long-term treatment (no development of tachyphy-
laxis) has also been shown [8, 9, 20]. They were also
effective in menstrual-related migraine attacks [21]. Head-
to-head studies did not establish the superiority of one
triptan over the others [22]. Preference trials suggest that
no ideal triptan exists for all patients, but the treatment
must be tailored taking into account the characteristics of
each patient and of the attacks [23–26]. Headache recur-
rence occurs in about 25–40 % of patients [8, 27, 28].
Observations When a triptan is administered early at the
beginning of attack, it has a greater efficacy [29–31]. About
25–35 % of patients do not respond to a particular triptan,
in which case other triptans can be tried [32–37]. In the
case of an unsatisfactory response to a triptan or headache
recurrence, a NSAID can be used [38]. Sumatriptan is
available in all formulations (subcutaneous, tablet, nasal
spray, suppository); subcutaneous sumatriptan is the most
effective drug in the class [39–41]. Rizatriptan and
zolmitriptan are available in rapid-dissolving formulations
(RPD) which have an effectiveness similar to that of tablet
formulations of the same drugs at the same dosages [42,
43]. Pharmacokinetics findings do not show higher blood
levels reached at shorter times for RPD formulations. The
latter can, however, be useful because they are easier to use
without need of water, particularly when moderate or
severe nausea is present. Naratriptan is not available in
Italy. In some studies oral triptans at lower dosages have
not demonstrated to be superior to some NSAIDs, simple
or combination analgesics [21]. Oral triptan formulations
are superior to oral ergotamine which has a low bioavail-
ability (\1 %). Ergotamine and dihydroergotamine have an
efficacy similar to that of triptans but induce more frequent
adverse events [44–47]. The excessive use of triptans
(C10 days a month) exposes the patient to the risk of
migraine chronification and should be avoided [48]. The
concurrent use of triptans and NSAIDs seems to have a
greater efficacy compared with that of triptans alone and is
associated to lower headache recurrence [41–52]. Side
effects are mostly mild-to-moderate, of short duration
(10–15 min) and include triptan syndrome (chest and neck
tightness, chest pain) in 4–5 % in patients treated with s.c.
sumatriptan and 2–4 % with the oral formulation, fatigue,
somnolence, dizziness and facial flush [6, 204–207]. Car-
dio- and cerebrovascular severe adverse events (myocar-
dial infarction, ictus), without an established cause–effect
Table 4 Levels of recommendation for the pharmacological treat-
ment of primary headaches
Level I Drugs with high efficacy supported by statistically
significant data (evidence of at least two controlled,
randomized studies versus placebo or versus active
drugs of proven efficacy) or very high clinical benefit
for patients (clinical effectiveness ???) and with no
severe adverse events
Level II Drugs whose value of efficacy is statistically of lower
significance compared to drugs of group I and with a
less significant clinical benefit for patients (clinical
effectiveness ??) and no severe adverse events
Level III Drugs showing efficacy from a statistical point of view
but not from a clinical point of view (contrasting results
or evidence is not conclusive). The drugs belonging to
this group were further subdivided into two subgroups:
(a) Drugs with no severe adverse events
(b) Unsafe drugs or with complex indications for use (e.g.
special diets) or important pharmacological interactions
Level IV Drugs of proven efficacy but with frequent and severe
adverse events or drugs whose efficacy has not been
proven from a clinical or statistical point of view
(no difference with respect to placebo). Drugs with
unknown clinical patient benefit or statistical
significance of efficacy (data unavailable or insufficient)
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relationship, were rarely reported. ECG modifications are
also rarely reported [53]. Dystonic crises, akathisia, eupho-
ria, can also rarely occur. Contraindications to triptans are
uncontrolled blood hypertension, coronary artery disease,
history of ischemic stroke, pheripheral artery disease, preg-
nancy and lactation and age [65 years.
Warnings
Pregnancy and breastfeeding From findings obtained by
pregnancy registries, a greater number of preterm newborns
or newborns with low birth-weight due to the use of suma-
triptan during pregnancy have been described. In the case of
repeated administration of sumatriptan in the first trimester
there is no increased risk of newborn malformations but the
sumatriptan use in the second and third trimester is associated
with atonic uterus and bleeding[500 ml at delivery. Infor-
mation on the safety of triptans during breastfeeding is limited
but reassuring, because the minimal quantities secreted with
milk are insufficient to induce adverse events to the child [54].
According to Italian Health Ministry Regulatory Agency the
use of triptans is not recommended under 18 years of age with
the exception of sumatriptan nasal spray 10 mg and zolmi-
triptan nasal spray 2.5 mg, which may be used in patients over
12 years of age [55, 56]. Also, according to this Agency, the
use of triptans after 65 years of age is not recommended. They
can be used only with a therapeutic plan approved by an
Ethical Committee and with informed consent [57].
Pharmacological interactions
Ergot derivates A triptan can be used at least 24 h after
ergot derivate administration. After taking a triptan it is nec-
essary to wait at least 6 h before taking an ergot derivate.
SSRI antidepressants A serotoninergic syndrome can
occur in the case of contemporary use of triptans and consists
in motor incoordination, marked asthenia and hyperreflexia.
MAO-A inhibitors They should be suspended at least 2 weeks
before starting triptan treatment. Propranolol increases the
concentration of rizatriptan. In the case of concomitant
administration of propranolol, rizatriptan should be used at the
dosage of 5 mg for the single attack, at the maximum daily
dosage of 10 mg. After taking propranolol, it is necessary to
wait at least 2 h before taking rizatriptan. Drugs which are
metabolized via CYP450 Eletriptan, rizatriptan and zolmi-
triptan may interact with drugs metabolized via CYP450 such
as oral contraceptives and antimicotics. The clinical relevance
of these observations needs to be clarified [58].
NSAIDs and analgesics
Indications They are indicated for the treatment of mild or
moderate attacks or when triptans are contraindicated or
ineffective [59, 60]. Efficacy The most consistent evidence of
efficacy is available for paracetamol, acetylsalicylic acid
(ASA), lysine acetylsalicylate, naproxen sodium, ibuprofen,
diclofenac sodium and potassium, metamizole and ketorolac,
whereas the evidence of efficacy for other NSAIDs is more
limited [61–65]. Head-to-head studies have not shown a clear-
cut superiority of a NSAID over another. Few studies have
evaluated the efficacy of analgesics and NSAIDs on associated
symptoms and functional disability. There is evidence only for
ASA, salicylates, ibuprofen and diclofenac sodium. There are
no studies supporting the consistency of efficacy and recurrence
rates for the majority of analgesics/NSAIDs. The efficacy of
ASA and other NSAIDs on migraine aura has never been tested.
Observations ASA is recommended in patients with car-
dio- and cerebrovascular comorbidities. Paracetamol is first-
choice drug for migraine attacks during pregnancy. The
excessive use of NSAIDs (C15 days a month) should be
avoided for the risk of migraine chronification. There is evi-
dence of the use of ketorolac i.v. in the emergency department
(ED), supporting its efficacy in the treatment of migraine
attacks even if the results are less favourable than those
obtained with prochlorperazine [66, 67]. In the same setting,
ketorolac has been demonstrated to be more effective than
sumatriptan nasal spray [68]. Metamizole, both by oral and
intravenous route, has been demonstrated to be effective in the
treatment of migraine attacks, but the risk of agranulocytosis
and hypotension as relevant side effects should be considered
[6]. Side effects consist mainly in gastrointestinal adverse
events (from gastric pain to gastric or duodenal ulcer). The
percentage of adverse events found in clinical trials con-
cerning the use of NSAIDs for migraine attack are lower than
those detected in studies regarding their daily use. These
adverse events, occasional in migraine patients using some-
times NSAIDs, can occur with higher frequency in the case of
daily or almost daily use by chronic migraine patients. Con-
traindications include severe renal and hepatic failure, hem-
orrhagic risk, gastric or duodenal ulcer.
Warnings Few NSAIDs can be used in patients under 14
years of age (ibuprofen, ketoprofen, morniflumate). NSA-
IDs should be administered with caution in elderly patients.
Pharmacological interactions Cumarol derivates or hepa-
rin (with the exception of those with low molecular weight):
more risk of bleeding in the case of contemporary use with
analgesics or NSAIDs. Alcohol should be avoided by con-
comitant use of analgesics or NSAIDs. Digoxin, barbiturates,
lithium: NSAIDs increase their plasma concentration. Aldo-
sterone, antagonists and potassium saving diuretics and anti-
hypertensive drugs: NSAIDs reduce their efficacy.
Ergot derivatives
Indications Their use should be restricted to low frequency,
severe attacks unresponsive to other drugs for their
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potential risk of abuse [69]. Efficacy Ergotamine tartrate
with or without caffeine and dihydroergotamine have been
demonstrated to be effective versus placebo or versus an
active drug in reducing migraine headache [70, 71].
Ergotamine tartrate is not effective on nausea or vomiting;
rather, because of the interaction with dopaminergic
receptors, it may itself induce or increase nausea or vom-
iting accompanying the migraine attack [72]. Studies are
lacking for its use for migraine aura. Ergotamine tartrate
administration is associated with low incidence of recur-
rence (\30 %) [70]. Oral ergotamine is inferior to suma-
triptan and eletriptan [44, 45].
Observations Dihydroergotamine, the drug of the class
with the best risk–benefit ratio, is not available in Italy.
Because nausea and vomiting may worsen due to the
administration of ergot derivates, the contemporary
administration of an antiemetic is generally indicated [72].
Caffeine doubles the rate of absorption of ergotamine and
increases its peak blood concentration. This explains the
development of combination formulations.
Patients who overuse ergotamine derivatives may
develop rebound headaches. The abuse of ergot derivatives
may induce an increase in the frequency of attacks and
develop into a chronic headache. Therefore, these drugs are
recommended for sporadic attacks and cannot be used for
more than 10 days/month [48].
Major side effects Nausea, vomiting, diarrhoea and
ergotism [73]. Ergotamine has a teratogenic effect [74].
Contraindications Cardiovascular and cerebrovascular
diseases, uncontrolled blood hypertension, Raynaud dis-
ease, renal failure, pregnancy and lactation. Pharmaco-
logical interactions Triptans: an ergot derivate should not
be administered within 6 h after the administration of a
triptan. Beta-blockers: an increase in the risk of peripheral
vasoconstriction has been observed in patients who also
used beta-blockers. The majority of patients are able to
tolerate such association; caution is necessary for particu-
larly sensitive patients [58].
Combination analgesics
Indications They have the same indications of simple
analgesics and NSAIDs. Few studies have been performed
on these combination drugs [75]. Efficacy has been dem-
onstrated only for the association with acetylsalicylic acid,
paracetamol and caffeine. Recent trials have demonstrated
a significant efficacy on migraine attacks of moderate
intensity and moderate disability [76]. This association has
been demonstrated to be effective in migraine attacks
related to the menstrual cycle [76]. Recent data suggest that
the effectiveness of the association of indomethacin ?
caffeine ? prochlorperazine is similar to that of triptans,
even though supporting studies are needed [77, 78].
Combination analgesics available in Italy include acetyl-
salicylic acid ? acethaminophen ? propyhenazone, acetyl-
salicylic acid ? acethaminophen ? indomethacin (with/
without caffeine), and acetaminophen ? propyphenazone
and acetaminophen ? codeine. Dosages of active sub-
stances in the combinations are different from those tested
for migraine attacks. The efficacy of acetylsalicylic
acid ? acethaminophen ? propyphenazone and butalbi-
tal ? propyphenazone ? caffeine has never been investi-
gated in RCT for migraine.
Observations To avoid the risk of abuse, the use of
combination analgesics should be limited to B10 days/
month; abuse can lead to headache chronification [79–81].
Side effects and contraindications in combination analge-
sics are the same as those for each component. Caffeine
may induce anxiety and insomnia.
Antiemetics
Indications Antiemetics are to be considered adjuvants,
especially when nausea and vomiting are prominent [82].
Efficacy Most studies have concerned the association of
antiemetics with analgesics and NSAIDs (naproxen, para-
cetamol, tolfenamic acid) or dihydroergotamine [72].
These associations have been proposed to improve the
absorption of the symptomatic drugs and to act as adju-
vants in reducing nausea or vomiting associated with the
attacks. No RCT, however, clearly demonstrated a supe-
riority of this association over NSAIDs alone. There is
some evidence that suggests that the use of an antiemetic
may improve the efficacy of a triptan [83]. Metoclopra-
mide, prochlorperazine and chlorpromazine have also
shown a modest antimigraine effect, besides a clear anti-
emetic effect [84, 85].
A modest antimigraine effect has been demonstrated for
metoclopramide administered intramuscularly or intrave-
nously [86].
Prochlorperazine or chlorpromazine administered intra-
muscularly or intravenously have been shown to be modestly
effective in studies carried out in the ED. Oral prochlorpera-
zine has also shown some partial efficacy [87, 88].
Dated findings on a limited number of patients support
some efficacy of domperidone in preventing migraine
attacks or reducing head pain intensity [326–328].
Intramuscular or intravenous formulations can be used
in the treatment of attacks of severe intensity in which
nausea and vomiting are prevailing and in the case in which
other symptomatic drugs are contraindicated or sedation is
needed. They can be considered as single drugs for the
treatment of migraine in particular clinical settings (i.e.
emergency department).
Side effects Metoclopramide may rarely induce dysto-
nia, tardive dyskinesia and akathisia. The more frequent
J Headache Pain (2012) 13 (Suppl 2):S31–S70 S35
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adverse events are somnolence and sedation. Rare adverse
events are acute dystonic crises or akathisia and postural
hypotension, particularly when an antihypertensive drug is
coadministered.
The occurrence of adverse events due to phenothiazines
is facilitated by alcohol or propranolol, which raises their
plasma levels. Metoclopramide, prochlorperazine and
chlorpromazine should not be coadministered with nar-
cotics, sedatives, hypnotics and tranquilizers due to the
synergic effects on the central nervous system. Prochlor-
perazine and chlorpromazine may lower the seizure
threshold; they should be used with caution in patients with
epilepsy. Contraindications Metoclopramide is contrain-
dicated in patients affected by pheochromocytoma, epi-
lepsy and in combination with neuroleptics such as
phenothiazines, butyrophenones, MAOIs.
Antiemetics are not recommended in patients with pro-
lactinoma. The use of metoclopramide, chlorpromazine and
prochlorperazine must be limited only to cases of extreme
necessity in pregnancy and during breast feeding [89].
Pharmacological interactions Anticholinergic drugs and
antiacids may antagonize the effects of metoclopramide
and domperidone on gastric motility.
Other drugs
Simple or combination opioid analgesics Controlled stud-
ies have demonstrated the association of paracetamol with
codeine, doxilamine or buclizine to be no more effective
than paracetamol alone [90]. In a more recent study the
combination of paracetamol ? codeine has been shown to
be more efficacious than ASA [91]. The association of
ASA with dextropropoxyphen and phenazone was not
more effective than ergotamine [92].
Also, butorphanol (not available in Italy) by intramus-
cular route has not shown to be more effective than dihy-
droergotamine administered intravenously in association
with metoclopramide.
There are no studies comparing butorphanol nasal spray
with other non-opioid symptomatic antimigraine drugs
[93, 94]. A double-blind study comparing the efficacy of
ketorolac (60 mg) and meperidine (75 mg)/promethazine
(25 mg), both administered by intramuscular route, did not
show a statistically significant difference between the two
drugs [95].
More recently, tramadol administered by intravenous
route alone or in combination with paracetamol has been
demonstrated effective in the acute treatment of migraine
[96–98].
The Ad Hoc Committee has unanimously decided that
this class of drugs does not represent a valid option for the
symptomatic treatment of migraine attacks. This is due to
the lack of data demonstrating their effectiveness compared
with other symptomatic drugs and because of the potential
risk of abuse and developing a chronic headache [99].
Other drugs
Barbiturates
There is no data supporting the efficacy of this class of
drugs in the treatment of migraine crises [100]. Barbitu-
rates may induce intoxication, addiction and dependence.
High dosages may induce withdrawal syndrome after dis-
continuation. Their use should be avoided for the potential
risk of abuse, rebound headache and chronification of
migraine.
Lidocaine
Limited evidence is available suggesting the effectiveness
of this drug administered intravenously for the treatment of
migraine attacks and in the chronic, refractory migraine
unresponsive to other treatments, with or without symp-
tomatic drug overuse [101].
Results of randomized, double-blind studies indicate a
modest, but significant efficacy although with frequent and
early recurrence [102, 103].
Steroids
Available findings are conflicting and do not allow definitive
conclusions to be drawn on their effectiveness in the treatment
of migraine attacks, particularly in the case of refractory
attacks and in reducing headache recurrence [104–108]. Ste-
riods are indicated for the treatment of status migrainosus.
The group of experts recommends dexamethasone
administered by intravenous route at a dosage of 10 mg or
prednisone administered by oral route at a dosage of
50–100 mg in the treatment of status migrainosus, even
though there are no consistent results from controlled trials
versus placebo.
Limited findings are available for metilprednisolone [109,
110]. One study demonstrated the superiority of the associa-
tion of dexamethasone and a triptan compared with triptan
alone in the treatment of menstrual migraine attacks [111].
Valproic acid
The drug administered by intravenous route at the dosage
of 300–800 mg has been demonstrated to be effective in
the treatment of migraine attacks. The promising results
obtained need to be confirmed in double-blind, placebo-
controlled studies involving a larger sample of patients
[112].
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Gepants
They have been developed in recent years, and preclinical
and clinical data suggest a role for calcitonin gene-related
peptide (CGRP) in determining migraine attacks.
They include telcagepant (formerly MK-0974) whose
efficacy has been shown in a study involving 500 migraine
patients with good tolerability profile. The compound BI
44370 in a phase II study has shown its superiority com-
pared with placebo at a dosage of 400 mg; phase III studies
are still on going [113].
Further CGRP antagonists are currently being developed
and a considerable expansion in this particular therapeutic
area is expected. Currently these drugs are not available in
the market and it is still too early to anticipate when they
will be available for use in a clinical setting.
Levels of recommendation
Table 5 shows symptomatic antimigraine drugs with levels
of recommendation I and II.
Table 6 includes symptomatic drugs with levels of
recommendations III and IV.
Preventive treatment
1. A good response to prophylactic treatment is obtained
if there is at least a 50 % reduction in the frequency
and severity of migraine attacks and a significant
improvement in the quality of life is reached.
2. To minimize side effects and improve patient’s
compliance, the most appropriate drug should be taken
at the lowest dosage, preferentially as a monotherapy.
Doses can be slowly increased until therapeutic goals
are achieved without side effects.
3. Prophylactic treatment should be maintained for at
least 3 months. Clinical benefit may take some time to
be obtained.
4. Prophylactic drugs should be chosen based on patient’s
comorbidities.
5. Particular attention should be devoted to drug–drug
and drug–food interactions.
6. Most preventive drugs may have a teratogenic effect.
Women should use a safe contraception.
7. Prophylactic treatment during pregnancy should be
limited to special situations, and in these cases drugs
with lowest risk for the foetus should be preferred.
Preventive drugs
Preventive drugs include beta-blockers, calcium channel
blockers, 5HT antagonists, antidepressants, antiepileptic
drugs, angiotensin inhibitors, dihydroergotamine, botu-
linum toxin A and supplements [114, 115].
Beta-blockers
These drugs are to be preferred in the case of hypertension
or tachycardia [116, 117].
Their efficacy as preventive drugs for migraine has been
fortuitously demonstrated in migraine patients with con-
current hypertension. The efficacy of atenolol, nadolol,
timolol, bisoprolol and nebivolol is supported by few
controlled studies [118–124]. Even though prophylactic
treatment is generally not advisable in pregnancy, pro-
pranolol may be used with relative safety [125]. The abrupt
suspension of these drugs can induce an increase in the
frequency of migraine attacks and an increase of blood
pressure.
Adverse events include fatigue, depression exacerbation
and nightmares, which are the most frequent, while asthma,
orthostatic hypotension, impotence, hallucinations and
weight gain occur less frequently.
Contraindications include congestive heart failure,
atrio-ventricular block, peripheral artheriopathy, Raynaud
syndrome, asthma, diabetes and depression.
Calcium channel antagonists are particularly recom-
mended for patients with anxiety and insomnia [126].
Efficacy Flunarizine is the most used drug. Cinnari-
zine has a good antimigraine action although few studies
have been carried out to investigate its efficacy in
migraine [127, 128]. There are insufficient data sup-
porting the efficacy of nimodipine and ciclandelate in
migraine [129]. Therapeutic effects become evident only
after some months of treatment. Cinnarizine induces the
CNS side effects and accumulation phenomena less
frequently.
Side effects of flunarizine are somnolence, asthenia,
weight gain, depression and extrapyramidal symptoms
in the long-term treatment and occur more frequently
in elderly patients; cinnarizine can induce somnolence
and epigastric pain which can be avoided by taking the
drug on a full stomach, weight gain, extrapyramidal
symptoms in the long-term treatment and occur more
frequently in elderly patients [130–132].
Contraindications include Parkinson’s disease or extra-
pyramidal disturbances, obesity, pregnancy and breast
feeding.
Antidepressants: tricyclics
Among tricyclics, there are only two double-blind studies
versus placebo supporting the efficacy of amitryptiline
[133–135].
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Table 5 Drugs for the symptomatic treatment of migraine with a level of recommendation I and II
Drug Dosage (mg) Level of
recommendation
Comments
5HT1B/1D agonists
Sumatriptan
Subcutaneous 6 Rapid onset of action compared to the other
formulations
Tablet 50–100 I
Suppository 25 Useful when oral route is not possible due to
nausea
Nasal spray 20 Useful when oral route is not possible due to
nausea
Zolmitriptan Rapid onset of action
Tablet 2.5
Oral disintegrating tablet 2.5 I
Nasal spray 2.5–5
Rizatriptan Rapid onset of action. The optimal dosage is
10 mgTablet 5–10 I
Oral disintegrating tablet 10 Recommended dosage is 5 mg in patients
treated with propranolol which increases the
plasma concentration of rizatriptan
Eletriptan
Tablet 20, 40 I The optimal dosage is 40 mg
(best efficacy/tolerability ratio)
The dosage of 20 mg is recommended in the
case of renal or liver failure
Almotriptan
Tablet 12.5 I Good tolerability profile
Frovatriptan
Tablet 2.5 I Long half-life, good tolerability profile
Ergot derivatives
Ergotamine oral, rectal, subcutaneous 1–2 II Indicated in the case of infrequent migraine
attacks. Risk of abuse and headache chronification.
An excessive use may cause ergotism
NSAIDs
Acetylsalicylic acid (ASA) oral 500–1,000 I Good efficacy/tolerability profile
Gastrointestinal adverse events
Lisine acetylsalicylate oral 500–1,000 I Good efficacy/tolerability profile
Gastrointestinal adverse events
Lisine acetylsalycilate i.v. 1,000 I To be used in a hospital setting. Risk of bleeding
Diclofenac–K? oral 100 II In the case of frequent migraine attacks risk of
abuse and headache chronification
Diclofenac–Na? i.m. 75 II
Flurbiprofen oral 100–300 II
Ibuprofen oral 400–1,200 I
Ibuprofen oral 200 II
Ketoprofen i.m. 100 II
Ketorolac i.m. or i.v. 30–60 II Clinical trials have been performed in particular
settings (emergency departments)
Metamizole (dipirone) i.v. or oral 1,000 II Potential risk of agranulocytosis [0.1 % and
hypotension (i.v. formulation)
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Amitryptiline is the first-choice drug particularly in
patients with comorbid anxiety and depression or with
concomitant tension-type headache.
Prophylactic effectiveness is obtained with doses lower
than those used for depression (10–20 mg/day) [135].
The most frequent adverse events are antimuscarinic
effects such as dry mouth, constipation and sedation. Often
an increase in appetite (craving) with a consequent weight
gain, or occasionally orthostatic hypotension and impo-
tence, may occur [134].
Contraindications include cardiac arrhythmias, prostatic
hypertrophy, glaucoma and epilepsy.
Serotonin norepinephrine reuptake inhibitors (SNRIs),
selective serotonin reuptake inhibitors (SSRIs)
and noradrenergic and specific serotonergic
antidepressants (NaSSAs)
Promising data have been obtained for venlafaxine but RCT
have some methodological limitations [136–138]. Although
paroxetine, escitalopram, fluvoxamine and sertraline are
sometimes used for migraine prophylaxis due to their good
tolerability profile, available data are limited and contrasting
[139–143]. There are no data available for mirtazapine. There
is also some positive evidence for fluoxetine [144, 145].
Venlafaxine can be useful in patients with depression
and concomitant anxiety. Fluoxetine can induce insomnia,
fatigue, tremor and epigastric pain. SSRI can interfere with
5HT1 agonists.
Antiepileptic drugs
Sodium valproate and topiramate are first-choice drugs in
the treatment of high-frequency migraine attacks, chronic
migraine, with and without symptomatic drug overuse and
in the case of comorbid epilepsy [146, 147].
Sodium valproate and topiramate are effective in both
migraine with and without aura and in chronic forms. Their
long-term efficacy has been shown [148–153]. The dosages
useful for the prophylactic treatment of migraine are lower
than those used for epilepsy. Gabapentin has a good tolera-
bility profile [154]. In open studies, lamotrigine (50–200 mg/
day) has been shown to be effective in the treatment of high-
frequency migraine attack with aura [155–157]. It is ineffec-
tive in migraine without aura [158]. Promising data have been
obtained for zonisamide, levetiracetam, pregabalin and need
to be confirmed.
Contraindications are hepatitis, pancreatitis, thrombocytemia
for sodium valproate; liver and kidney insufficiency, kidney
stones, glaucoma for topiramate; hypersensitivity to the drug for
gabapentin and lamotrigine. All antiepileptics are contraindi-
cated during pregnancy due to their teratogenic effect [159].
Adverse events caused by sodium valproate include
asthenia, dizziness, tremor, alopecia, weight gain, menstrual
disorders, hepatopathy and pancreatitis; for topiramate,
asthenia, memory problems, anomia, weight loss, paresthesia,
dysgeusia and depression; rare adverse events include meta-
bolic acidosis, kidney stones, psychosis and narrow-angle
glaucoma; for gabapentin asthenia, somnolence, ataxia, dip-
lopia and constipation; for lamotrigine: skin rashes (which
may be warning signs of Stevens–Johnson syndrome; to
reduce this risk a slow titration is recommended), somnolence,
gastroenteric disturbances and ataxia [160].
5HT-antagonists
5HT-antagonists are the oldest drugs available for migraine
prophylaxis and include methysergide, a semisynthetic
Table 5 continued
Drug Dosage (mg) Level of
recommendation
Comments
Naproxen oral 500–1,500 I
Na ? Naproxen oral 550–1,500 I
Mefenamic acid per os 500 II Effective in menstrual migraine attacks
Combination analgesics
Paracetamol ? acetyl salicylic
? caffeine suppository
500 ? 500 ? 130 To be used for attacks of moderate intensity.
Effective also in the treatment of menstrual
migraine. In the case of frequent migraine
attacks, risk of abuse and headache chronification
Indomethacin ? prochlorperazine
? caffeine oral
25 ? 2 ? 75 I In the case of frequent migraine attacks, risk of
abuse and headache chronification
Indomethacin ? prochlorperazine
? caffeine suppository
25–50 ? 4–8 ? 75–150 II See above
Paracetamol ? codeine per os 400–650 ? 6–25 II See above
Antiemetics
Metoclopramide i.v. 0.1 /kg 1-3 times II To be used in a hospital setting
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derivative of ergometrine, which is not available in Italy
and pizotifen, a serotonin antagonist with modest antihis-
taminic and cholinergic effects, which is a second-choice
drug due to its side effects [161].
There are a few dated clinical studies supporting the
efficacy of pizotifen [162–165]. This drug has a long half-
life (about 23 h) and can be used in a unique dose
(0.5–1.5 mg), for cycles of 3 months.
Contraindications include glaucoma, arrhythmias, uri-
nary retention and obesity.
The most frequent side effects are somnolence, increase in
appetite, weight gain, xerosthomia and constipation [166].
Angiotensin inhibitors
Indications Lisinopril and candesartan are second-choice
drugs to be considered for patients with a concomitant
hypertension [167–169]. There is only one positive RCT
for both drugs [170, 171].
Contraindications are angioedema, bilateral stenosis of
renal artery for lisinopril; hypersensitivity to sulphona-
mides, hypokaliemia, hypercalcemia, liver and kidney
insufficiency and gout for candesartan.
Adverse events for lisinopril are asthenia, hypotension,
dry cough, hyperkalemia, gastrointestinal disturbances and
impotence; for candesartan asthenia, dizziness, tachycardia
and hyperuricemy.
Other drugs Two ergot derivatives, controlled release
dihydroergotamine 10 mg/day and dihydroergocryptine
20 mg/day (not available in Italy), can be taken into
account as second-line treatments [172, 173]. Riboflavin at
high doses (400 mg) showed a certain efficacy in pre-
venting migraine, with few side effects (moderate
abdominal pain, diarrhoea), in one RCT [174]. This drug is
available as a galenic preparation in Italy. Among herbal
remedies, butterbur root extract (Petasites hybridus), at the
dosage of 150 mg/day, proved to be effective in two RCTs,
while another herbal drug, Tanacetum parthenium, studied
in several RCTs, gave more conflicting results [175, 176].
One controlled study versus placebo demonstrated the
efficacy of Coenzyme Q10 (100 mg 9 3 per day) [177]. The
superiority of tiotic acid, a drug which also increases brain
energetic metabolism, has also been shown compared with
placebo [178]. Conflicting findings have been obtained for
pidolate magnesium (400–600 mg/day) [179, 180]. The use of
non-chelated formulations determines diarrhoea at clinically
efficacious doses. It can be used in women with menstrual
migraine and premenstrual syndrome, but a precise adminis-
tration schedule has not been established (646–648). Onabo-
tulinumtoxinA showed some efficacy in various open studies
in migraine patients, but contradictory results emerged in
double-blind controlled studies versus placebo concerning
patients with episodic migraine [181]. These studies used
different protocols, individualized or standardized, different
inoculation sites and groups with different frequency of
attacks (see chronic migraine).
Menstrual migraine In pure menstrual migraine or
menstrually related migraine, a short-term prophylactic
therapy around menses can be tried if menstrual cycles are
regular and migraine attacks are predictable [182]. Two
different strategies may be followed: (1) administration of
symptomatic drugs, in particular triptans, on a regular basis
instead of on demand; (2) administration of estrogens, to
avoid the premenstrual oestrogen fall that is thought to be a
main cause of menstrual migraine. In the first case,
frovatriptan (5 mg/day) or zolmitriptan (5–7.5 mg/day)
may be administered [183–185]. Positive results have also
been obtained in one RCT for sumatriptan 100 mg and for
naproxen sodium (1,100 mg/day) [186]. The administra-
tion should be limited to the period -2 ?4/5 days from
menstrual onset. If the second option is chosen, estradiol
gel (1.5 mg/day) or transdermal estradiol patch (100 lg)
are probably the best choices [187, 188].
Chronic migraine Only recently some RCTs have been
carried out in patients affected by the most disabling form
of migraine, i.e. chronic migraine. Two drugs have so far
showed some evidence of efficacy: topiramate and onab-
otulinumtoxinA. Topiramate (100 mg/day) has been par-
tially effective also in patients with medication overuse;
onabotulinumtoxinA (injection every 12 weeks) has given
a statistically significant clinical benefit [189–191].
Data supporting a significant efficacy of onabotulinum-
toxinA have been obtained in patients with chronic migraine
with or without symptomatic drug overuse [192–194].
Levels of recommendation
Table 7 shows prophylactic drugs with levels of recom-
mendation I and II. Table 8 includes preventive drugs with
levels of recommendation III and IV.
Tension-type headache (TTH)
Acute attack treatment
Just like in migraine, the treatment of the acute episode is
necessary. Patients should record attack frequency, dura-
tion and severity in a headache diary to monitor the disease
course and the effectiveness of therapy.
General considerations
1. The most appropriate drug should be taken at the first
symptoms and at the lowest dosage useful to obtain a
complete resolution of the crises and as early as possible.
J Headache Pain (2012) 13 (Suppl 2):S31–S70 S41
123
Table 7 Drugs for the preventive treatment of migraine with a level of recommendation I and II
Drug (by oral route) Daily
dosage
(mg)
Level of
recommendation
Comments
Beta-blockers
Propranolol 80–240 I Useful in patients with hypertension, anxiety and panic disorders. It can exacerbate
depression. Do not use with ergotamine. Increase doses gradually. Particularly useful
in patients with essential tremor. Most frequent adverse events are fatigue, mood
disorders, nightmares. Other side effects are bradicardia, orthostatic hypotension,
impotence, hallucinations, weight gain
Metoprolol 50–200 I Same indications and side effects as for propranolol, excluding essential tremor
Atenolol 100 I Same indications and side effects as for propranolol, excluding essential tremor
Bisoprolol 5–10 II Same indications and side effects as for propranolol, excluding essential tremor
Nadolol 40–240 II
Calcium channel blockers
Flunarizine 5–10 I Use administration schedules with periodic suspensions (i.e. 5 days/week or 3 weeks/
month), to avoid the accumulation of the drug
Most frequent side effects are weight gain, sedation and depression. Extrapyramidal
symptoms may be observed in elderly patients. The recommended dose to reduce
adverse events is 5 mg
Cinnarizine 75–150 II Most frequent side effects are weight gain and drowsiness
Antidepressants tricyclic
Amitriptyline 10–75 I Dosages tested in clinical trials, the majority of them dated, are in general higher than
those usually used in clinical practice for prophylactic treatment of migraine
A progressive increase in doses is recommended until maintenance doses are reached
in order to reduce adverse events
Most frequent side effects are drowsiness, weight gain and anticholinergic symptoms.
Particularly useful in patients with depression, concurrent migraine and tension-type
headache. Higher doses should be used in patients with comorbid depression
Antiepileptic drugs
Sodium valproate 500–1,500 I Controlled release formulations are available with a better tolerability profile.
Recommended for patients with prolonged or atypical migraine aura. Not
recommended in patients with liver disease and haemorrhagic diathesis. A
progressive increase in doses is recommended. Frequent adverse events include
nausea, asthenia, somnolence. Other side effects include weight gain, hair loss and
tremor. Teratogenic potential
Topiramate 50–100 I Gradual increase of dosage is recommended. Frequent, not serious adverse events
include paresthesiae, memory and concentration disturbances, nausea, weight loss
and drowsiness. Rare serious adverse events include kidney stones, narrow-angle
glaucoma
Gabapentin 900–2,400 II Recommended for elderly patients. Well tolerated
5HT-antagonists
Pizotifen 1.5 II Frequent adverse events include weight gain and somnolence
Other drugs
Dihydroergotamine 10 II Do not use within 6 h after triptan administration. Useful for intermittent or short-term
prophylaxis. Withdrawal could be associated with rebound headache
Dihydroergocriptine 20 II Mild side effects. Withdrawal could be associated with rebound headache
Onabotulinum toxin
type A
155–195 Ua IV (episodic
migraine)
I (chronic
migraine)
The majority of controlled studies have not provided conclusive results in episodic
migraine
It is effective in chronic migraine. Costs are comparable to topiramate 100 mg for a
period of treatment of 3 months and lower than topiramate for a period of 4 months
a Dosage referred to each inoculation
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2. Formulations containing solely one active drug should
be preferred.
3. The patient should fill in a headache diary to evaluate
headache recurrence, treatment efficacy and potential
side effects.
4. The choice of the symptomatic drug/s should be based
on the careful and critical consideration of clinical
data, the mechanism of action and side effects of the
drugs.
Symptomatic drugs
Drugs for TTH attacks include NSAIDs, simple analgesics,
antiemetics and other drugs.
NSAIDs
Scientific evidence supports the efficacy of acetylsalicylic
acid (ASA), diclofenac, ibuprofen, ketoprofen, metamizol
(dipyrone) and naproxen [195–205].
ASA, ketoprofen and naproxen are first-choice drugs.
ASA is especially useful in the case of comorbid cere-
brovascular or cardiovascular disease, but is to be avoided
in patients with gastric disease. Low doses of NSAIDs are
usually sufficient to obtain a therapeutic result. Ibuprofen is
reported to have minor gastric adverse effects. Compara-
tive studies were not able to demonstrate the superiority of
one drug because the comparisons were not based upon
equivalent doses of the different molecules [196, 198–201,
204, 205]. The assumption of NSAIDs or simple analgesics
for 15 days or more per month, for[3 months, can induce
a chronification of headache and a chronic medication-
overuse headache.
For contraindications, drug interactions and side
effects, see the paragraph on migraine.
Simple analgesics
Paracetamol has been tested in TTH patients showing good
efficacy and tolerability [196, 200, 204]. It is a first-choice
Table 8 Drugs for the preventive treatment of migraine with a level of recommendation III and IV
Drug Route of
administration
Daily
dosage
(mg)
Level of
evidence
Scientific
strength of
evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
SNRI and SSRI
Fluoxetine os 10–40 B ? ? Frequent, not
severe
III
Venlafaxine os 75–150 B ? ? Occasional, not
severe
III
Angiotensin inhibitors
Lisinopril os 5–20 B ? ? Occasional, not
severe
III
Candesartan 16 B ?? ? Rare, not severe III
Antiepileptic drugs
Lamotrigin os 50–200 B ?? ??? (only
migraine
with aura)
Occasional, not
severe
III
5HT1 antagonists
Methysergide 2–8 A ??? ?? Potentially severe IIIa
Other drugs
Ribloflavin 400 B ?? ? Rare, not severe IIIb
Magnesium 400–600 B ?? ? Rare, not severe IIIb
Petasites hybridus 100–150 B ?? ? Rare, not severe IIIc
Tanacetum parthenium 18.75 B ? 0/? Rare, not severe IIIc
Thiotic acid 600 B ? ? Rare, not severe IIIc
a Not available in Italy
b Not available in Italy at the recommended dosages
c Available in Italy as a herbal product or as an over-the-counter product
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drug both in pregnancy and in patients with gastric disease
but it should be used with caution in subjects with liver
disease.
Combination analgesics with caffeine, codeine and
butalbital share indications with simple analgesics and are
more effective than the latter. The combination drugs with
caffeine (paracetamol ? caffeine, paracetamol ? ASA ?
caffeine and ibuprofen ? caffeine) are classified at rec-
ommendation level I [206–210]. Also, the association of
indometacin ? prochlorperazine ? caffeine was demon-
strated to be effective in one study [207].
An excessive and frequent use of combination analgesics
(for 10 days a month or more) should be avoided because of
the high risk of drug abuse, headache chronification and drug-
induced headache. Paracetamol ? codeine (500 ? 30 mg)
and butalbital ? propyphenazone ? caffeine (50–150 ?
125–175 ? 25–75 mg) are recommended at the level III
because of the addiction potential [211, 212]. Patients taking
opiates or barbiturates should be informed about the risks
deriving from an abrupt discontinuation and undergo a hos-
pitalized drug discontinuation schedule. Combination anal-
gesics share the same contraindications, drug interactions
and side effects of the single components (for details see
‘‘Migraine’’).
Antiemetics are generally not necessary in the usual
management of TTH acute therapy. Intravenous metoclo-
pramide, however, was found to be effective in the emer-
gency treatment of TTH episodes [213]. Also, intravenous
administration of chlorpromazine was effective in the ER
TTH management [214].
Complementary or alternative drugs Promising results
have been obtained with a topical preparation of pepper-
mint oil 10 g and ethanol (90 %) to 100 [215, 216]. Tiger
balm has also shown to have a modest but significant effect
in inducing headache relief [217].
Preventive treatment
General considerations
1. A preventive therapy is recommended in the case of
headache-related disability for C4 days/month or poor
response to symptomatic treatment even if the head-
ache frequency is lower.
2. Treatment is considered effective if it reduces attack
frequency and/or severity by at least 50 %.
3. The identification of trigger factors and their elimina-
tion, when possible, contribute to reduce attack
frequency [218].
4. Comorbid diseases play a main role in the choice of
therapy (e.g., the use of amitriptyline is contraindi-
cated in prostatic hypertrophy and glaucoma).
5. Particular attention should be devoted to drug
interactions.
6. Preventive therapy should always be based on a single
drug which should be titrated to the lowest effective
and well tolerated dose.
7. No recommendations are available concerning the best
duration of treatment.
8. Patients should be involved in the choice of treatment
and it is advisable to use a limited number of
administrations (compliance is in fact inversely pro-
portional to the number of administrations).
9. Patients should also be informed on how and when
drugs should be taken, on their potential side effects
and their efficacy. Patients should be advised to record
their attacks in the headache diary to verify frequency
and duration of headache, functional impairment,
number of symptomatic drugs taken, efficacy of
prevention treatment and possible side effects.
Preventive drugs
Drugs for prevention therapy of TTH include antidepres-
sants (tricyclics, SSRI, other antidepressants), muscle
relaxants, benzodiazepines and other drugs.
Antidepressants
Among tricyclics amitriptyline is a first-choice drug. It is
also recommended in case of comorbidity with anxiety,
insomnia, depression or migraine [219, 220]. Amitriptyline
is utilized at much lower dose for TTH than that necessary
to obtain an antidepressive effect. A slow titration of the
drug is recommended to increase its tolerability and avoid
adverse events.
Contraindications include cardiac arrhythmias, prostatic
hypertrophy, glaucoma and epilepsy. It should be used with
caution in the elderly because of its anticholinergic action.
For side effects see paragraph on migraine. Also, clomip-
ramine (150 mg/die) and desipramine (75 mg/die) may be
useful [221, 222].
SSRI are less effective than amitriptyline but better
tolerated [223, 224]. Fluvoxamine was the most studied
molecule in this class. Also fluoxetin and paroxetin showed
some evidence of efficacy.
Other antidepressants
Mirtazapine, a specific noradrenergic and serotoninergic
antidepressant, is another first-choice drug which is espe-
cially indicated in the case of comorbid anxiety, insomnia
and depression [225, 226]. It should be taken at low initial
doses because it can induce sedation and sleepiness.
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Promising results come from venlafaxin, a noradrenalin
and serotonin selective reuptake inhibitor (SNRI), which
is able to reduce headache frequency independently of
the association with anxiety or depression [227, 228].
Maprotiline and mianserine are other antidepressants that
have shown to be effective in TTH preventive therapy
[229, 230]. The latter was compared to both clomipramine
and fluvoxamine with similar efficacy [221]. No conclusive
results have been obtained for nefazodone [231] and
ritanserine [232, 233], not available in Italy; sulpiride has
been used at the dosage of 30 mg/day and has been shown
to be more effective than paroxetine [234].
Muscle relaxants
One RCT supports the use of tizanidine in chronic head-
ache including TTH. The drug was slowly titrated over
4 weeks to 24 mg or the maximum tolerated dose showing
moderate adverse effects (somnolence, dizziness, dry
mouth, asthenia) [235, 236]. In one study cyclobenzaprine
has demonstrated to be effective in the improvement or
complete relief of headache in half of 20 TTH patients,
whereas only partial relief was obtained in one-third of
patients treated with placebo [237].
Benzodiazepines
In dated studies diazepam (5 mg/day) seemed to be more
effective than placebo in reducing headache frequency
[238, 239]. It can be useful in the case of comorbid anxiety.
Also, alprazolam (0.75 mg/day) has been demonstrated to
be effective in TTH preventive therapy with a lower level
of rating (level of recommendation III) [240].
Other drugs
Positive results have been obtained with topiramate
(25–100 mg/die), which was tested at the initial dose of
25 mg/die titrated to 100 mg/die in chronic TTH patients
in a recent open study [241]. Buspirone, a non-benzodi-
azepine anxyolitic drug, has been compared to amitripty-
line, showing moderate results in a small sample of patients
[220]. Further investigation is needed (level of recom-
mendation III). L-5-hydroxytryptophan at the daily dose of
300 mg showed mild efficacy in the prophylaxis of chronic
TTH in one RCT (level of recommendation III) [242].
Conflicting results have been found with onabotulinum-
toxinA which may be attributed, at least in part, to vari-
ability of doses, study protocols, inoculation sites and
Table 9 Drugs for the symptomatic treatment of tension-type headache with a level of recommendation I and II
Drug Dosage (mg) Level of
recommendation
Comments
Analgesics and NSAIDs
Acetylsalicylic acid oral 500–1,000 I Good efficacy and tolerability profile. Not
recommended in pregnancy and in gastric
disease
Diclofenac–K? oral 12.5–50 II
Ibuprofen oral 400–800 II Reduced gastric damage
Ketoprofen oral 50–100 II
Lumiracoxib 200–400 II
Metamizol (dipyrone) oral 500–1,000 II Potential risk of agranulocytosis [0.1 %
and of hypotension
Metamizol (dipyrone) intravenous 1,000 II Tested to treat TTH in the emergency room.
Potential risk of agranulocytosis [0.1 %
and of hypotension
Naproxen oral 275–550 I
Paracetamol oral 500–1,000 I Use with caution in patients with epatic
failure
Combination analgesics
Ibuprofen ? caffeine oral 400 ? 200 II Risk of abuse and headache chronification
with frequent use
Indometacin ? prochlorperazine
? caffeine oral
25 ? 2 ? 75 II See above
Paracetamol ? caffeine oral 500–1,000 ? 30–130 I See above
Paracetamol ? acetyilsalicylic acid
? caffeine oral
200–1,000 ? 500 ? 30–50 I See above
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headache frequency of enrolled patients. Further studies are
needed (level of recommendation IV) [243, 244].
Levels of recommendation
Table 9 shows symptomatic drugs for TTH with levels of
recommendation I and II. Table 10 includes symptomatic
drugs with level of recommendation III.
In Table 11 preventive drugs for TTH with levels of
recommendation I and II are listed. Table 12 reports pre-
ventive drugs with level of recommendation III.
Cluster headache (CH)
Treatment of CH is a difficult challenge and needs the
active participation of the patients, who should be reas-
sured on the benign nature of his/her headache. They
should be informed on the drugs available for preventing or
interrupting attacks and that at present there are no treat-
ments able to prevent active periods and modify the natural
history of the disease. CH patients should be advised on
factors that may precipitate attacks during an active phase,
in particular, alcoholic beverages that should therefore be
avoided.
Acute attack treatment
Treatment of CH attack should not be delayed. Drugs
should be promptly bioavailable and this can be attained if
they are administered by parenteral or subcutaneous route
[245, 246].
The objectives of a correct and effective symptomatic
treatment are (1) to treat the attack when it starts; (2) to
obtain pain relief as soon as possible (possibly within
15 min from the administration of the drug); (3) to limit to
a minimum the adverse events [247].
Symptomatic drugs
Sumatriptan
Its efficacy has been demonstrated for the subcutaneous
(s.c.) and intranasal formulations. Sumatriptan s.c. (6 mg)
has been shown to be effective both on pain and associated
symptoms [248–250]. When administered for long periods,
it maintains its efficacy without tachyphylaxis and with a
good safety profile [251, 252]. The efficacy of sumatriptan
nasal spray (20 mg in a nostril) has been shown within
30 min after administration in a double-blind randomized
study [253]. The greater latency of action suggests its use
for attacks lasting at least 45 min. Sumatriptan nasal spray
does not have the indication for cluster headache in Italy.
The most common adverse events are reactions in the site
of injection, dizziness, paraesthesia, sensation of cold or
warm and irritation of the nostril for the intranasal for-
mulation. In 90 % of cases they are mild or moderate
[254].
Zolmitriptan
Its efficacy has been demonstrated for the oral and intra-
nasal formulations. Oral formulation (5 and 10 mg) has
been demonstrated to be effective at 30 min (reduction of 2
points of pain intensity in a 5-point scale) in one RCT
[255]. In Italy the only dosage available is 5 mg (to be
reached only once within 24 h if needed). Zolmitriptan
nasal spray (5 and 10 mg) has also been shown to induce
CH relief in two RCTs, with a higher efficacy for the
10-mg formulation and with few adverse events for both
dosages [256–258].
A Cochrane analysis of six randomized studies, con-
trolled versus placebo, demonstrated that sumatriptan and
zolmitriptan are superior to placebo [254]. Adverse events
of triptans include paraesthesia, asthenia, nausea, dizzi-
ness and irritation of the nostril for the intranasal
formulation.
Oxygen by inhalation
The efficacy of oxygen inhalation at the flow of 7 l/min for
15 min has been shown in dated open studies and in a more
recent controlled crossover study versus room air [259]. In
a further randomized study using an oxygen mask and
oxygen flow of 12 l/min a complete remission of cluster
headache attacks both in the episodic and chronic forms
was obtained within 15 min in 78 % of cases versus 20 %
for room air [260]. In the case of no response to usual
recommended flow it may be increased to 14–15 l/min
[261].
Ergotamine derivatives
Dated studies have shown the efficacy of ergotamine
tartrate 250 lg i.m. (only 1 study vs. placebo), ergota-
mine tartrate (1 mg) plus caffeine (100 or 200 mg) tablets
(in a study also in association with bellafoline 100 mg)
and ergotamine tartrate (2 mg) plus caffeine (100 mg)
and dihydroergotamine nasal spray for the acute treat-
ment both in patients with episodic and chronic forms
[262–266].
Anaesthetics
Contrasting results have been obtained for lidocaine
intranasal (4 %) in open studies [101, 267, 268]. Better
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results were achieved in a study using 10 % lidocaine
solution with respect to saline [269].
The application of a solution of cocaine 10 % in both
nostrils has been shown to block the attack in a controlled
study versus placebo (saline solution) in patients with
episodic and chronic cluster headache [269, 270]. No sig-
nificant adverse events were recorded with the exception of
a mild state of arousal in a patient who had abused the
drug. Cocaine is not available in Italy as medication.
Somatostatin and somatostatin analogues
Two randomized controlled trials are available, one for
somatostatin i.v. (25 lg in 50 ml saline) and one for
Table 10 Drugs for the symptomatic treatment of tension-type headache with a level of recommendation III
Drug Dosage (mg) Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Combination analgesics
Paracetamol ? codeine oral 500 ? 30 B ?? ?? Occasional, not severe
Butalbital ? propyphenazone
? caffeine oral
50–150 ? 125–175 ? 25–75 B ?? ?? Occasional, not severe
Antiemetics
Metoclopramide intravenous 10 B ? ? Moderate, not severe
Chlorpromazine intravenous 10 B ?? ?? Frequent
Complementary alternative drugs
Peppermint with ethanol (90 %) to 100 topic 10 B ?? ?? Not recorded
Tiger balm topic Not defined B ?? ? Not recorded
Table 11 Drugs for the preventive treatment of tension-type headache with a level of recommendation I and II
Drug Dosage
(mg)
Level of
evidence
Scientific
strength of
evidence
Clinical
effectiveness
Adverse events Level of
recommendation
Comments
Antidepressants
Amitriptyline 25–75 A ??? ??? Frequent, not severe I Useful in patients with
comorbid anxiety,
depression, insomnia.
Contraindicated in the
case of glaucoma and
prostatic hypertrophy
Clomipramine 10–150 B ?? ?? Frequent, not severe II
Fluvoxamine 50–100 B ?? ?? Frequent, not severe II
Maprotilin 75 B ??? ?? Frequent, not severe II
Mianserin 30–60 A ?? ? Frequent, not severe II
Mirtazapine 15–30 A ??? ??? Frequent, not severe I Particularly indicated in
patients with anxiety,
depression, insomnia. It
may induce somnolence
Venlafaxine 75–150 B ?? ?? Frequent, not severe II
Muscle relaxants
Tizanidine
oral
3–12 B ??? ??? Frequent, not severe II Especially useful in the
case of pericranial muscle
tenderness
Benzodiazepines
Diazepam 5 B ?? ?? Occasional, not severe II
Other drugs
Topiramate
oral
25–100 C ??? ??? Frequent, not severe.
Rarely severe
II
J Headache Pain (2012) 13 (Suppl 2):S31–S70 S47
123
octreotide i.v. (an analogue with longer half-life: 1.5 h,
100 lg in 1 ml vehicle) demonstrating a significant
reduction of pain in 20 and 30 min. respectively [271, 272].
Most common side effects are nausea, diarrhoea and
meteorism.
Preventive treatment
Preventive treatment is a fundamental part of the man-
agement of active CH, which cannot be obtained only with
the acute treatment due to the high frequency, suddenness
and shortness of the attacks. A symptomatic treatment
alone should be limited, in the episodic form, to active
phases of short duration (mini cluster). The objectives of
the preventive treatment are (1) the rapid disappearance of
attacks and the resolution of active periods; (2) the
reduction of frequency, intensity and duration of attacks
[245, 246, 273].
The effectiveness of preventive treatment can be evaluated
with certainty only in the chronic form, because in the episodic
form there is always the doubt that the active period runs out
spontaneously and not because of the treatment.
1. Preventive treatment must start early in the active phase.
2. Treatment must continue for at least 2 weeks after
disappearance of attacks.
3. Treatment must be suspended gradually.
4. If the attacks reappear, dosages must be increased to
therapeutic levels.
5. Treatment must be re-started at the onset of a
subsequent active period.
6. The choice of the drug depends on different factors:
age and lifestyle of the patient (avoid alcohol intake
during the cluster period); expected duration of the cluster
period; type of CH (episodic or chronic); response to
previous treatments; reported side effects; contraindica-
tions to recommended drugs; comorbid diseases.
7. Polytherapy, tested in a few trials, is indicated only in
patients resistant to monotherapy or patients who do
not tolerate recommended drugs at optimal dosage.
Preventive drugs
Verapamil
In a double-blind controlled study versus placebo this drug
at the dosage of 120 mg 9 3 per day has demonstrated to
be effective in patients with episodic CH. In these patients
it is indicated as first-choice drug [274]. In the chronic
form, according to two open studies and one head-to-head
study versus lithium carbonate, it was effective in 50–55 %
of the patients [275–277]. Dosages used were higher than
those used for the episodic form (up to 960–1,200 mg). In
the comparison study verapamil was effective more rapidly
with fewer side effects [276]. The most relevant adverse
events include arrhythmia (19 % of cases) and bradycardia
(36 %); ECG monitoring of patients is recommended to
avoid an atrioventricular block and symptomatic brady-
cardia [274, 278, 279]. In Italy, verapamil is not indicated
for cluster headache.
Lithium salts
Results are available from some dated open studies and two
RCTs demonstrating the effectiveness of this drug in the
Table 12 Drugs for the preventive treatment of tension-type headache with a level of recommendation III
Drug Dosage
(mg)
Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse events
Antidepressants
Desipramine 75 C ? ?? Frequent, not severe
Fluoxetine 20 C ? ?? Frequent, not severe
Paroxetine 20–30 B ? ? Frequent, not severe
Nefazodone 100–450 C ?? ?? Frequent, not severe
Ritanserin 10 B ? ? Frequent, not severe
Sulpiride 30 B ? ?? Frequent, not severe
Muscle relaxants
Cyclobenzaprine oral 10 B ?? ?? Frequent, not severe
Benzodiazepines
Alprazolam oral 0.75 B ? ? Occasional, not severe
Other drugs
Buspirone 30 C ? ? Frequent, not severe
L-5-hydroxytryptophan oral 300 B ? ? Occasional, not severe
None of the drugs evaluated by the group of experts were included at level of recommendation IV
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preventive treatment of chronic CH. In the two RCTs,
dosages were 300 mg 9 3 per day and 800 mg/day,
respectively [277, 280, 281]. Blood lithium levels should
range from 0.4 to 0.6 mmol/l. The most frequent adverse
events include tremor, gastrointestinal disturbances, dizzi-
ness and polyuria [281, 282].
Steroids
In a retrospective study, prednisone (10–80 mg/day) induced
a significant reduction (72 % of cases) or a complete remis-
sion (58 % of cases) of attacks within 3–10 days in a small
sample of CH patients with episodic or chronic form, with the
best results obtained for dosages C40 mg [283]. When dosage
was gradually reduced, (\20 mg) the attacks reappeared. The
drug is recommended for short-term usage (i.e., at the start of
other recommended preventive treatments).
Methylprednisolone i.v. (250 mg in 100 ml saline) fol-
lowed by prednisone per os (10 mg/day) induced a further
benefit in patients treated with optimal doses of verapamil
[284]. The i.v. administration of methylprednisolone (30 mg/
kg in 500 ml of saline in 3 h) induced the interruption of the
cluster period for 2–3 days, with a subsequent prompt reap-
pearance of attacks [285]. No significant side effects were
observed for both drugs at the used dosages.
Serotonin antagonists
Methysergide has been tested only in dated open studies
which demonstrated an efficacy in 76–77 % of cases [286,
287]. The recommended dose is 8 mg (although the dosage of
16 mg has also been tested). The drug should be started with
the dose of 2 mg and should be increased gradually every
3–7 days. Side effects occur in 20–45 % of patients. The most
frequent include nausea, dizziness, stomach pain, restlessness,
somnolence and cramps. The drug should not be used for more
than 6 months due to the possible development of retroperi-
toneal and lung fibrosis [288]. It is not available in Italy.
Pizotifen (1–4 mg/day), in a dated double-blind study,
showed a certain efficacy in a limited number of patients with
episodic CH (reduction[50 % of attack frequency in 36 % of
the cases and interruption of cluster period in 21 %) [289].
Lisuride has been administered at variable dosages from 0.075
to 0.400 mg/day to patients with episodic and chronic cluster
headache in an open study. In all patients the drug induced a
benefit without relevant side effects [290]. Lisuride is avail-
able in Italy at the dosages of 0.2–0.5 mg and does not have
the indication for CH.
Antiepileptics
A positive effect of sodium valproate (1–2 g/day) had been
suggested by an open study but was not confirmed by a
more recent RCT [291, 292]. In the latter study, drug/
placebo was administered for 2 weeks and 50 % of
responders were identified in the valproate group versus
62 % of placebo group [292]. Two open studies showed an
effect of topiramate at different dosages (50 and 125 mg/
day and 25–200 mg/day, respectively) with a remission
within about 3 weeks from the beginning and a reduction
of duration of the cluster period; a RCT (50–250 mg/day)
did not show a superiority of topiramate compared with
placebo [293–295]. After obtaining promising results in a
single case, gabapentin has been tested in three open trials
involving a limited number of patients at doses ranging
from 800 to 3,600 mg/day. The drug, administered for
4–6 months, reduced significantly the frequency and
intensity of attacks or interrupted the cluster period in at
least 50 % of cases and was well tolerated [296–299]. Most
of the antiepileptics listed above do not have the indication
for CH in Italy.
Ergotamine derivatives i.m. ergotamine has been tested
in an open study involving a limited number of patients
during the active phase at dosages ranging from 0.25 to
0.50 mg/day to 0.25 mg four times per day. It induced a
complete disappearance of attacks in all the patients
without a reduction of cluster period. Side effects were
somnolence, anorexia, bad taste and daze [300]. Dihydro-
ergotamine i.v. was evaluated in two retrospective studies
involving hospitalized patients. In the first study dihydro-
ergotamine at the dosage of 0.5 mg three times per day
interrupted the cluster period in patients with both episodic
and chronic forms, refractory to other preventive treat-
ments. In the second study dihydroergotamine i.v.
(0.5 ? 1 mg) and dihydroergotamine nasal spray 1 mg or
dihydroergotamine s.c. at the dosage of 0.5–1 mg induced
the disappearance of attacks or a reduction [50 % of
attacks in 88 % of patients with episodic and 57 % of
patients with chronic CH [301, 302]. Side effects were mild
and only a few patients had to discontinue the drug.
Histamine
After the first observations of Horton (838), one dated open
study involving few patients demonstrated that histamine
sulphate i.v. (2.75 mg in 250 ml the first day, followed by
11 mg in 500 ml saline in the subsequent 9 days) induced a
reduction of 75–100 % in one-third of cases, of 10–49 % in
an another one-third of cases and no effect in the remaining
cases [303].
Triptans
They were proposed for the short-term prophylaxis at the
beginning of the cluster period instead of steroids (defined
also as transitional therapy) or for the short-term
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prophylaxis of mini cluster. A reduction of the attacks was
observed for frovatriptan (5 mg/day) in studies involving
episodic CH patients treated with verapamil (retrospective
study) and chronic CH patients resistant to preventive
treatments (open study) [304]. In an open study eletriptan
(40 mg two times per day for 6 days) induced 50 %
reduction of attacks in one-third of the cases [305].
Responders were all treated with verapamil, whereas non-
responders did not use preventive drugs. In a randomized
double-blind versus placebo study sumatriptan 100 mg
administered three times per day for 7 days did not induce
a significant reduction of attack frequency [306].
Capsaicin
A first study demonstrated that the bilateral application of
300 lg per nostril, repeated to reach a complete desensi-
tization, induced a significant reduction and disappearance
of the attacks, while a second study demonstrated that the
application in the ipsilateral nostril is equally efficacious,
whereas the application in the contralateral nostril was
ineffective [307, 308]. This effect was observed in the
majority of patients with both episodic and chronic CH
after 10 days of treatment. In the chronic patients after
25–40 days from the last application of capsaicin the
attacks reappeared. Capsaicin is not available in Italy.
Melatonin
Its efficacy at the dosage of 10 mg per os has been tested in
a limited number of patients with episodic form demon-
strating the ability of the drug to reduce significantly the
attack frequency. In responders this effect was obtained in
3–5 days [309, 310]. These promising results were not
confirmed in a further pilot study involving patients with
episodic CH [311].
Levels of recommendation for symptomatic and pre-
ventive drugs are reported in Table 13.
Other trigeminal autonomic cephalgias (TACs)
Paroxysmal hemicrania
Due to the low prevalence of this form, few studies have
been carried out regarding the treatment of paroxysmal
hemicrania (PH).
They are, in general, non-standardized, open, non-con-
trolled studies and at times the studies lack relevant clinical
information data, such as the effective duration of the treat-
ment, the dosage of tested drugs and the patient follow-up.
PH, by definition, is a headache responsive to indo-
methacin and therefore, the diagnosis should be
reconsidered in patients not responding to this drug at
effective dosages (200 mg) [312–314].
Other drugs have been tested in PH patients who do not
tolerate indomethacin. They include verapamil, COX-2
selective inhibitors (rofecoxib, colecoxib) and piroxicam
[315–320].
Short-lasting unilateral neuralgiform headache
with conjunctival injection and tearing (SUNCT)
This rare headache form is also included in the TACs group
and is therefore difficult to carry out controlled randomized
clinical studies on its treatment [246].
Available data for several drugs have been obtained
from case reports with limited patient series and rarely
from observational studies.
In particular, studies involving lidocaine i.v. have been
carried out on a few patients, whereas only case reports are
available using i.v. or oral steroids [321].
Studies with more conspicuous patient series concern
antiepileptic drugs used for preventive treatment. They
include carbamazepine, gabapentin, topiramate and lamo-
trigine [321]. The most studied antiepileptic drug is lam-
otrigine due to its good efficacy and discrete tolerability.
Levels of recommendation
It was impossible to define levels of recommendation for
all drugs used for preventive treatment of PH and SUNCT
because of the limited number of patients tested.
For both headache forms, levels of evidence, scientific
strength of evidence, clinical effectiveness and side effects
are reported in Tables 14 and 15.
Primary headaches management in particular
conditions
Emergency Department
In the Emergency Department (ED) acute treatment must be
simple, based on a few drugs with a clear evidence of efficacy,
administrable through rapid absorption routes (rectal, intra-
muscular or endovenous) and rapidly effective [358].
Migraine
Among NSAIDs, ketorolac 60 mg, administered intra-
muscularly, followed by a subsequent dose of 30 mg after
8 h, has been shown to be more effective than intranasal
sumatriptan, but less effective than phenotiazines in
relieving migraine attacks in the ED [67, 68, 359].
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Another first-choice treatment is ASA 1,000 mg with or
without metoclopramide [360]. Metamizole has been
shown to be significantly more effective than placebo. Its
potential side effects should be taken into account includ-
ing severe hypotension, agranulocytosis and allergic reac-
tions [361].
Positive data are available for dihydroergotamine 2 mg
nasal spray or suppository but the drug is not available in
Italy and is less effective than sumatriptan and phenoti-
azine [71].
Subcutaneous, intranasal and rectal sumatriptan should
be available in the ED and it may be particularly useful in
migraine patients with nausea and/or vomiting [362–364].
Some evidence on the efficacy of 1 mg of magnesium
sulphate by intravenous route in the treatment of migraine
attacks in the ED needs to be confirmed [365].
In the presence of nausea and vomiting 10 mg meto-
clopramide by intramuscular route can be useful, even if
occasional adverse events with this drug should be con-
sidered including sedation, akathisia, acute dystonic crises
and other extrapyramidal symptoms such as stiff neck and
oculogyric crises [84].
Among the other antiemetics, ondansetron 4–8 mg by
intravenous route may be used.
Prochlorperazine has been shown to be more effective
than placebo, metoclopramide and other agents in the
Table 14 Level of evidence, scientific strength of evidence, clinical effectiveness, adverse events of preventive drug for Paroxysmal Headache
Drug Daily
dosage (mg)
Level of
evidence
Scientific strength
of evidencea
Clinical
effectiveness
Adverse events No. of
cases
References
Indomethacin 25–50 C 0/? ? – 1 [322]
Indomethacin 75 C 0/? ??? Occasional, not severe 8 [323–330]
Indomethacin 150 C 0/? ??? – 2 [330, 331]
Indomethacin 200–225 C 0/? ?? Occasional, not severe 3 [331, 332]
Verapamil 480 C 0/? ? – 1 [333]
Piroxicam-b-cyclodextrine 20–40 C 0/? ?? – 6 [334]
Rofecoxib 25 C 0/? ??? – 1 [317]
Rofecoxib 50 C 0/? ??? Occasional, not severe 2 [317, 318]
Celecoxib 400 C 0/? ??? – 1 [319]
Verapamil 240–320 C 0/? ?? – 10 [320]
a The scientific strength of evidence has been indicated as 0 (inefficacy)/?because there is no comparison with placebo or one active agent but
sometimes the efficacy of the tested drug has been demonstrated
Table 15 Level of evidence, scientific strength of evidence, clinical effectiveness, adverse events of preventive drugs for SUNCT
Drug Daily
dosage (mg)
Level of
evidence
Scientific strength
of evidencea
Clinical
effectiveness
Adverse
events
No. of
cases
References
Topiramate oral 75 C 0/? ?? Mild 2 [333]
Topiramate oral 50 C 0/? ??? – 1 [334]
Carbamazepine oral 200 C 0/? ?? – 1 [335]
Carbamazepine oral 400 C 0/? ??? – 1 [336]
Carbamazepine oral 600–1,000 C 0/? ? – 5 [337–340]
Carbamazepine oral 2,000 C 0/? ? – 1 [341]
Gabapentin oral 800–2,700 C 0/? ??? – 3 [342–344]
Lamotrigine oral 100–200 C 0/? ?? – 12 [345–350]
Lamotrigine oral 300–400 C 0/? ??? – 2 [351, 352]
Verapamil 480 C 0/? ? – 1 [353]
Topiramate oral 200 C 0/? ??? – 1 [354]
Methylprednisolone oral B1 /kg C 0/? ??? – 3 [355]
Oxcarbazepine and gabapentin oral 600/400 C 0/? ?? Mild 1 [356]
Lidocaine i.v. 1.3 /kg/h C 0/? ??? – 1 [357]
a The scientific strength of evidence has been indicated as 0 (inefficacy)/? because there is no comparison with placebo or one active agent but sometimes
the efficacy of the tested drug has been demonstrated
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symptomatic treatment of migraine attacks in the ED [366,
367]. In association with diphenhydramine, prochlorpera-
zine has been shown to be more effective than sumatriptan
and sodium valproate i.v. [363, 368]. Its most frequent
adverse event is sedation.
Meperidine, an opioid analgesic, although effective,
may cause frequent adverse events such as sedation, dis-
orientation, akathisia, gastrointestinal disturbances [369].
Furthermore, it can induce addiction and dependence and
therefore it is not recommended by the group of experts.
Benzodiazepines (especially diazepam 5–10 mg,
administered by i.v.) are useful in case of concomitant
anxiety.
In the status migrainosus and in the treatment of attack
recurrence, dexamethasone 10 mg followed by a sub-
sequent dose of 4 mg every 6 h can be used, even if there
are no consistent data on its efficacy in these two condi-
tions [104, 107, 370–373].
Tension-type headache
The group of experts suggests the use of NSAIDs, i.m. or
i.v., to obtain a more significant and rapid relief of pain in
the rare cases in which tension-type headache patients
present to the ED.
Oral benzodiazepines can also be useful in the case of
attacks of great intensity, particularly in patients with
concomitant anxiety.
Metoclopramide i.v. has demonstrated a modest anal-
gesic efficacy at the dosage of 10 mg [374].
The efficacy of chlorpromazine i.v., at the dosage of
10 mg, in tension-type headache patients presenting to the
ED has also been demonstrated [375]. The most frequent
adverse event is sedation, occasionally extrapyramidal
symptoms or akathisia may occur.
Cluster headache
Cluster headache attack, given its short duration, is rarely
treated in the ED. However, CH patients with frequent
daily attacks can refer to the ED. In these cases indications
for an adequate prophylaxis therapy should be provided
and patients should be addressed to a Headache Center,
possibly in the same hospital, to set up the most suitable
preventive treatment.
Headache management in pregnancy and lactation
Migraine
No studies are available on the use of both symptomatic
and prophylactic drugs in pregnant women. There are also
few data on the risk related to their use during pregnancy,
delivery and breast-feeding. Available recommendations
come from the Regulatory Agencies of the single countries
[376, 377].
It is worth noting the potential teratogenic risk of
methysergide, other ergot alkaloids and metoclopramide,
the use of which is unadvisable during pregnancy and
breast-feeding.
There are conflicting data on the potential risk of
foetal malformations, although rare, for amitriptyline. In
the case of its use during pregnancy, amitriptyline should
be suspended, at least 7 days before delivery to reduce
the likelihood of a neonatal withdrawal syndrome which
is characterized by respiratory distress and trouble
feeding. Amitriptyline should be avoided during lacta-
tion [378].
According to the group of experts, the majority of
symptomatic and prophylactic drugs are not recommended
during pregnancy [379, 380]. For symptomatic treatment,
the first-choice drug is paracetamol, particularly during the
first trimester of pregnancy. NSAIDs use, if needed, should
be limited to second and third trimester of pregnancy [381].
Use of triptans is unadvisable during pregnancy. Data from
pregnancy registries show a higher premature delivery
frequency and lower weights for newborns in comparison
with the average (sumatriptan), but no severe adverse
events or complications during delivery (sumatriptan, ri-
zatriptan) [54, 382–392].
In the case of nausea or vomiting during attacks, dom-
peridone is the best choice drug. Antiemetics and sedative
phenotiazinic drugs’ use is not recommended [393, 394].
Prophylactic drugs should not be used, or at least only
rarely, or at least used only rarely, during pregnancy, with
particular regard to antiepileptics due to their teratogenic
potential [395–397]. The only exceptions are magnesium
and beta-blockers (propranolol, metoprolol in the second
and third trimesters of pregnancy) for which there is no
evidence of teratogenicity (level of recommendation II for
both). Beta-blockers could have toxic effects on the new-
born and may be responsible for intrauterine growth
retardation, hypoglycemia, bradycardia and respiratory
depression [398]. They are not recommended in women
who present with migraine with aura during pregnancy;
they can be used, on the contrary, during lactation. In
unresponsive cases, dexamethasone or prednisone may be
used [399].
Tension-type headache
There are no studies on TTH during pregnancy. Paraceta-
mol should be preferred for the attack treatment. If pre-
ventive treatment is needed, non-pharmacological therapy
option should be preferred.
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Cluster headache
Pregnant women suffering from CH [400, 401] should be
informed on the treatment benefits and risks and on the
drug potential teratogenic effect. Dosage and number of
administrations should be reduced to the minimum.
Treatments to be preferred are oxygen, prednisone and
verapamil. The use of subcutaneous or intranasal suma-
triptan should be limited as much as possible. If verapamil
cannot be used, gabapentin should be preferred as pro-
phylactic treatment. During lactation, oxygen and suma-
triptan may be used as symptomatic drugs and prednisone/
prednisolone, verapamil and lithium for prophylaxis.
Headache management in the elderly
In several guidelines for primary headaches specific indi-
cations for the management of elderly headache patients
are lacking. Furthermore, specific controlled studies are
lacking and therefore recommendations are mainly based
on opinions of experts.
Migraine
Among migraine symptomatic drugs, the safest is para-
cetamol. NSAIDs may also be used, in absence of con-
traindications. They have however potentially severe
adverse events, particularly gastroenteric and renal side
effects [399].
Among antiemetics domperidone should be preferred to
metoclopramide which, particularly in the elderly, can be
responsible for extrapyramidal side effects.
Controlled studies on the use of triptans by patients over
65 years are lacking. From the few data available in the
literature, the use of triptans in a general population did not
demonstrate a greater frequency of cardio- and cerebro-
vascular complications in patients over 65 years without
vascular risk factors (1,037). In the experts’ opinion their
use is therefore possible in the presence of low frequency
of attacks, after a careful evaluation of cardio- and cere-
brovascular risks in the single patient. Conversely, ergot
derivatives are contraindicated due to their widespread
vasoconstrictive action. Use of combination drugs must be
limited due to the risk of abuse. The use of opioid drugs is
unadvisable because of the adverse events, such as disori-
entation, sedation and nausea [400].
First-choice drugs for prophylaxis are beta-blockers,
particularly atenolol, metoprolol and bisoprolol because of
their good tolerability profile [401]. Their contraindications
are chronic obstructive pulmonary disease, bradycardia or
ventricular hyperkinetic arrhythmias and depression. Beta-
blockers must be used with caution in presence of diabetes.
The use of flunarizine should be limited because of its
potential side effects with particular regard to extrapyra-
midal disturbance and parkinsonism.
In relation to the high prevalence of depression in the
elderly, antidepressants represent a good therapeutic option
[402]. Although effective, tricyclic antidepressants (ami-
triptyline, nortriptyline) are not free from adverse events,
which may be even severe, particularly in the elderly. They
include sedation, cognitive disturbances, cardiac rhythm
disturbances (tachycardia, hyperkinetic arrhythmias), pos-
tural hypotension, acute glaucoma and urinary retention,
particularly in patients with prostatic hypertrophy [403].
SSRI and SNRI are better tolerated but they have not
shown a significant efficacy for migraine prophylaxis in
randomized controlled studies. Their usefulness must be
evaluated in individual cases.
The use of antiepileptics should be limited to migraine with
a high frequency of attacks and in the case of comorbidity of
migraine with epilepsy. Topiramate and sodium valproate
should be preferred based on the greater availability of data
showing efficacy, but they are not free from adverse events. In
particular, topiramate may induce cognitive disturbances and
sedation and, rarely, is responsible for visual disturbances
(acute myopia onset, glaucoma) and nephrolithiasis. Topira-
mate use is contraindicated in the last two disturbances [403].
Sodium valproate, conversely, may cause tremors, ataxia
and hepatotoxicity (particularly in patients with previous
hepatic disturbances). Other antiepileptics with lesser evidence
of efficacy, but a higher tolerability profile can be alternatively
used, such as gabapentin and, in some cases, pregabalin [401].
Given the recent evidence of efficacy of lisinopril and
candesartan in migraine prophylaxis, their use can be
considered because of the good tolerability profile espe-
cially in the presence of hypertension.
Tension-type headache
There are no studies regarding the treatment of tension-
type headache in elderly patients. Paracetamol and NSA-
IDs are recommended for symptomatic treatment, keeping
in mind the considerations already reported for migraine.
Given the frequent comorbidity with depressive distur-
bances, antidepressants are the first-choice drugs among
preventive drugs. Mirtazapine, SSRI (fluoxetine, paroxe-
tine, fluvoxamine, sertraline, citalopram and escitalopram)
or SNRI (venlafaxine, duloxetine) should be preferred
because of their greater tolerability profile in comparison
with tricyclics, even if controlled and randomized studies
of elderly tension-type headache are lacking.
Drugs with fewer evidence of efficacy are tizanidine and
onabotulinumtoxinA for which, in the literature, data are
contrasting and, in the majority of cases, negative.
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Non-pharmacological procedures are often the only appli-
cable treatments although there is no evidence of their efficacy in
geriatric patients. It should be emphasized that the psychiatric
approach, if needed, is particularly difficult in elderly patient.
Cluster headache
Sumatriptan s.c. is not recommended because of the limitation
in its use by patients over 65 years of age and for the possible
occurrence of angina and hypertensive crises. The first-choice
drug is oxygen 100 %, by inhalation using a mask, at the rate
of 7 l/min for 15 min. For preventive treatment the best drug
for geriatric patients is verapamil which is well tolerated by
patients up to a dosage of 480 mg/day. Side effects for which
its suspension is recommended are rare (bradycardia, hypo-
tension, constipation, peripheral edemas). It can be useful to
associate melatonine with verapamil, at an evening dosage of
6–10 mg [402, 403]. In the case of an unsatisfactory response
to verapamil, the second choice drug is prednisone at the
dosage of 50 mg, in association with a proton-pump inhibitor.
Its use should be limited to a short period (7–14 days). The use
of lithium must be restricted to cases refractory to the other
prophylactic treatments given the low tolerability in the
elderly. The periodic plasma monitoring of lithium levels is
needed and values should be maintained within the thera-
peutic range (0.4–1.2 mEq/l).
There are no data regarding the use of sodium valproate
and topiramate by CH elderly patients in the unresponsive
chronic forms.
As far as the non-pharmacological therapies are con-
cerned, there are no data relative to the application in the
elderly of new procedures such as the hypothalamic deep
brain stimulation and greater occipital nerve stimulation.
With regard to the treatment of the other primary headaches
in the elderly, such as hypnic headache and paroxysmal
headache, one can refer to the papers recently published by our
subgroups of experts on other primary headaches (2–5).
Non-pharmacological therapy of primary headaches
Just as for the pharmacological therapy the non-pharma-
cological therapy includes a symptomatic and a preventive
treatment. The non-pharmacological techniques can be a
valid alternative or complementary treatment. They are
particularly indicated in the case of pregnancy, breast
feeding, multiple therapies for comorbid diseases, poor
tolerability of drugs, childhood and elderly.
Acute attack treatment
Most of the evidence for the techniques used in controlling
headache attacks is purely anecdotic because RCTs are
lacking. A study on 400 primary headache (including
migraine, TTH and CH) patients showed the scarce and
momentary efficacy of self-administered manoeuvres on
various regions of the head (compression, application of
cold or heat, massage). In spite of this, 46 % of the subjects
used the manoeuvres constantly, at each attack [404].
In migraine a study compared the efficacy of suma-
triptan with acupuncture showing a similar efficacy of the
two drugs but it should be pointed out that it is difficult to
apply acupuncture at the moment of attack [405].
Transcranial magnetic stimulation (TMS) determined a
reduction or the remission of pain in 69 % of migraine with
aura patients versus 48 % in the group treated with sham
technique (level of recommendation II) [406]. Some evi-
dence is available for the therapeutic blockade of greater
occipital and supraorbital nerves in migraine patients [407].
Preventive treatment
Biofeedback is the non-pharmacological technique of first
choice for migraine prophylaxis (level of recommendation I)
[408]. The effect of biofeedback is slower but more lasting
when compared with drug therapy. The association of bio-
feedback and pharmacological therapy induces a more
marked effect [409]. Conflicting results deriving from the
comparison with sham-acupuncture were obtained for acu-
puncture (level of recommendation II). However, in a recent
study, its efficacy was found to be similar to that of flunarizine
[410]. Acupuncture is contraindicated in the presence of
coagulation deficits, cardiac pacemaker, cardiac arrhythmias
and epilepsy. The expertise of the operator is fundamental.
Needles have to be sterilized to avoid infections. Other non-
pharmacological therapies, including relaxing techniques,
sleep therapies, spinal manipulations, stretching, mobiliza-
tion, physiotherapy and TMS, were rated at the level of rec-
ommendation III for migraine preventive therapy prophylaxis
on the base of the available scientific evidence.
Further studies with homogeneous methods are needed
to definitively demonstrate the efficacy of TENS, physical
activity, anaesthetic blockade of the greater occipital and
supraorbital nerves, diet restriction and orthodontic/gna-
thologic techniques (all of these were rated at level of
recommendation IV). Several retrospective studies and
three prospective studies (one of these was double-blind
placebo-controlled) monitoring the post operative course
after patent foramen ovale closure for cardiovascular
indications showed improvement of concomitant migraine
(level of recommendation III) [411, 412]. Promising results
come from the surgical deafferentation of muscle trigger
points in frontal, temporal and parietal regions (level of
recommendation IV).
Basing upon the current scientific evidence biofeedback
and acupuncture are the first-choice non pharmacologic
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therapies for the prophylaxis of tension-type headache.
Biofeedback shows a slower but more lasting therapeutic
effect than amitriptyline [409]. This technique induces a
greater efficacy when it is associated with other non
pharmacologic or pharmacologic options (level of recom-
mendation I) [413]. Acupuncture was found to be more
effective than drug preventive therapy and sham acu-
puncture and as effective as other therapies (physiotherapy,
relaxation programs and massage ? relaxation program) in
a Cochrane review of 11 studies [414]. For contraindica-
tions and limits of this technique, see above.
Many other non pharmacological treatments are useful
in the prevention of TTH, although further well-conducted
studies are needed to support their efficacy. They include
cognitive-behavioural therapy (as effective as amitriptyline
but slower) [415], short-term psychodynamic psychother-
apy (determining a lower rate of relapse in analgesic
overuse than placebo after weaning) [416], osteopathic,
chiropractic and massage protocols (contraindicated in the
case of fractures, bone lesions and osteoporosis) [417,
418], Physiotherapy/Physical Exercise (several techniques
showed to be effective but the results are not comparable
because non homogeneous methods have been used in
different studies) [419, 420] and orthodontic/gnathological
techniques (an intraoral removable device induced an
improvement similar to amitriptyline’s one) [421]. All the
aforementioned non pharmacologic techniques have been
rated at the level of recommendation III. Moreover, the
transcutaneous electrical nerve stimulation (TENS) is lar-
gely used in clinical practice to alleviate chronic pain but
no evidence is up to now available to demonstrate its
efficacy in TTH (level of Recommendation IV) [422].
Deep brain stimulation with stimulator implantation in
the posterior hypothalamus represents the most innovative
Table 16 Symptomatic non-pharmacological treatments for migraine
Treatment Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
References
Pain relieving manoeuvres – – 0 – IV [404]
Acupuncture – – ? – IV [405]
TMS B ?? ? – II [406, 427, 428]
Mechanical compression – – 0 – IV [429]
GON blockade C ?? ? – III [430]
TMS transcranial magnetic stimulation, GON greater occipital nerve
Table 17 Preventive non-pharmacological treatments for migraine
Treatment Level of
evidence
Scientific
strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
References
Biofeedback A ?? ?? – I [408, 409, 431, 432]
Relaxation C 0/? ? – III [433, 434]
Cognitive-behavioural treatment – – ? – IV [435–437]
Sleep C ?? ? – III [429, 438]
Chiropractic osteopathy C 0/? ? – III [419, 422, 439–441]
Physiotherapy C ? ? – III [442–444]
Acupuncture A ?? ? Rare II [445]
Transcutaneous electrical nerve stimulation (TENS) – – ? – IV [442]
Transcranial magnetic stimulation (TMS) C ? ? Rare III [428, 446]
Physical activity – – ? – IV [447]
Anaesthetic blockade C ? ? Rare IV [407]
Diet – – ? – IV [448]
Orthodontic and gnathological techniques C ? ? – IV [422, 449]
PFO Closure C ?? ? Rare, severe III [411, 412]
Occipital nerve stimulation C – ? Rare [450]
Trigger points deafferentation – – ? – IV [451]
PFO patent foramen ovale closure
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surgical technique for aborting chronic refractory cluster
headache. Pain relief has been obtained in 83 % of 16
cluster headache patients followed up for 5 years, with
61 % of patients completely free from pain [423]. The
efficacy of this approach has been confirmed in nine cluster
headache patients followed up for 2 years in 71 % of cases
[424]. In a recent double-blind, prospective, crossover
study versus sham stimulation involving 11 cluster head-
ache patients a reduction of attacks[50 % was observed in
six patients [425]. This technique is not free from risks: a
case of death for cerebral haemorrhage was reported in a
case series of seven cluster headache patients who under-
went hypothalamic deep brain stimulation [426]. It should
be reserved only to chronic cluster headache patients,
totally resistant to all therapeutic strategies (level of rec-
ommendation II).
Levels of recommendation
Levels of evidence, scientific strength of evidence and
clinical effectiveness for symptomatic and preventive non-
pharmacological treatments are reported in Tables 16 and
17 for migraine, Tables 18 and 19 for tension-type head-
ache and Tables 20 and Table 21 for cluster headache.
Conflict of interest None.
Table 18 Symptomatic non-pharmacological treatments for tension-type headache
Treatment Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
Reference
Pain relieving manoeuvres – – 0 – IV [404]
Table 19 Preventive non-pharmacological treatments for tension-type headache
Treatment Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
References
Biofeedback A ?? ?? – I [408, 413, 431]
Cognitive-behavioural treatment – – ? – IV [416, 435, 437, 452]
Strategic short-term psychotherapy – – ? – IV [417]
Chiropractic osteopathy C ? ? – III [418, 419]
Physiotherapy C ? ? – III [419, 427, 453–458]
Acupuncture A ?? ? Rare II [452]
Transcutaneous electrical nerve stimulation (TENS) – – ? – IV [422]
Physical activity – – ? – IV [421]
Pranotherapy – – ? – IV [459]
Orthodontic and gnathological techniques C ? ? – IV [414, 422, 449, 460]
Table 20 Symptomatic non-pharmacological treatments for cluster headache
Treatment Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
Reference
Pain relieving manoeuvres – – 0 – IV [404]
Table 21 Preventive non-pharmacological treatments for cluster headache
Treatment Level of
evidence
Scientific strength
of evidence
Clinical
effectiveness
Adverse
events
Level of
recommendation
References
Anesthetic blockade - - ? Rare IV [461]
Lesion of trigeminal nucleus C ? ? Rare, severe IV [462–467]
Occipital nerve stimulation C - ? Rare IV [468, 469]
Hypotalamic deep brain stimulation B ?? ??? Rare, very severe II (only for chronic
refractory CH)
[423, 470, 471]
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